Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebentafusp in Advanced Clear Cell Sarcoma
NCT06942442Phase 2Recruiting
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Start
- Oct 2025
- Primary completion
- Oct 2030
- Modality
- Bispecific Antibodies, TCR-Engineered T Cells, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, open-label trial of tebentafusp in clear cell sarcoma (CCS) (2 arms), sponsored by Sarcoma Alliance for Research through Collaboration. Primary endpoint: Measure Disease Response at 5.5 months. Started Oct 2025; status: recruiting.
02
Drugs
tebentafusp
03
Conditions
clear cell sarcoma (CCS)
Beyond the preview
Go deeper on NCT06942442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942442.